Highly potent and isoform-selective dual-site-binding tankyrase/Wnt signaling inhibitors that increase cellular glucose uptake and have anti-proliferative activity

Amit Nathubhai, Teemu Haikarainen, Jarkko Koivunen, Sudarshan Murthy, Francoise Koumanov, Matthew Lloyd, Geoffrey Holman, Taina Pihlajaniemi, David Tosh, Lari Lehtio, Michael Threadgill

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)
177 Downloads (Pure)

Abstract

Compounds 13 and 14 were evaluated against eleven PARP isoforms to reveal that both 13 and 14 were more potent and isoform-selective towards inhibiting tankyrases (TNKSs) than the “standard” inhibitor 1 (XAV939)5, i.e. IC50 = 100 pM vs. TNKS2 and IC50 = 6.5 µM vs. PARP1 for 14. In cellular assays, 13 and 14 inhibited Wnt-signaling, enhanced insulin-stimulated glucose uptake and inhibited the proliferation of DLD-1 colorectal adenocarcinoma cells to a greater extent than 1.
Original languageEnglish
Pages (from-to)814-820
Number of pages7
JournalJournal of Medicinal Chemistry
Volume60
Issue number2
Early online date16 Dec 2016
DOIs
Publication statusPublished - 26 Jan 2017

Fingerprint Dive into the research topics of 'Highly potent and isoform-selective dual-site-binding tankyrase/Wnt signaling inhibitors that increase cellular glucose uptake and have anti-proliferative activity'. Together they form a unique fingerprint.

Cite this